Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
69
resultados
Última actualización
09/03/2025 [06:45:00]
Resultados 25 a 50 de 69
Resumen de: US2025064722A1
The invention provides improved anti-BCMA CAR T cell compositions for adoptive T cell therapy for relapsed/refractory multiple myeloma.
Resumen de: US2025064928A1
Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof comprising administering to the subject a BCMAxCD3 bispecific antibody on a bi-weekly dosing schedule.
Resumen de: US2025064960A1
The present application relates to conjugates comprising an amatoxin, a target-binding moiety wherein the target is CD37, i.e., a CD37-binding moiety, and optionally a linker linking said amatoxin and said CD37-binding moiety. The invention further relates to the synthesis of said conjugates. In addition, the invention relates to a pharmaceutical composition comprising such conjugate for use in the treatment of immune cell, particularly B-cell and/or lymphoma associated diseases and/or malignancies (FIG. 1).
Resumen de: US2025064839A1
The present disclosure provides, inter alia, methods for treating cancers including leukemia using low doses of an anthracycline such as doxorubicin.
Resumen de: US2025064829A1
Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma (DLBCL)) using immunoconjugates comprising anti-CD79b antibodies in combination with an anti-CD20 antibody (such as rituximab) and one or more chemotherapeutic agents (such as gemcitabine and oxaliplatin).
Resumen de: US2025067745A1
T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sézary syndrome are the most frequent cutaneous T-cell lymphomas. Now the inventors showed the expression of CD38 by Sézary cells and in CD4+ blood cells of patients with Sezary syndrome. CD38 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CD38-expressing cancer cells would eliminate tumor cells.
Resumen de: US2025066360A1
The present invention relates to a pyridine-containing polycyclic derivative, and a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as a biological regulator in the preparation of a medicament for the treatment of autoimmune diseases, chronic inflammatory diseases, acute inflammatory diseases, autoinflammatory diseases, atherosclerosis, diabetes, fibrotic diseases, metabolic diseases, cancers, tumors, leukemia and lymphoma, wherein the definition of each substituent in general formula (I) is the same as that in the description.
Resumen de: US2025066326A1
Described are the bifunctional compounds, compositions and methods of treating a disease or disorder characterized by aberrant B-cell lymphoma 6 (BCL6) activity.
Resumen de: WO2025042742A1
Provided herein are compositions comprising multispecific (e.g. bispecific) antibodies that bind to CD3 and BCMA, such as alnuctamab, and methods of using such compositions to treat a patient having a disorder associated with BCMA expression (e.g. BCMA-expressing B-cell cancers, such as multiple myeloma).
Resumen de: WO2025040580A1
The present invention relates to killer cell immunoglobulin-like receptors (KIRs) and to immunotherapy against tumor and autoimmune diseases associated with an increased expression of the KIR3DL2 receptor. In particular, the present invention provides polypeptides and fusion proteins comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 1. This corresponds to a KIR3DX1 D2 domain wherein a deletion found in humans has been repaired. The invention discloses engineered KIR family receptors and CARs comprising the inventive polypeptides as antigen recognition domain. Further provided are nucleic acids encoding the polypeptides and receptors of the invention as well as cells expressing said receptors. The polypeptides, fusion proteins and cells of the invention as well as pharmaceutical compositions comprising the same may be used for the treatment of KIR3DL2- associated conditions such as rheumatic diseases including spondylarthritides, T cell leukemias including cutaneous T-cell lymphoma (CTCL), Sézary syndrome, mycosis fungoides, adult T-cell leukemia (ATL) or myelodysplastic syndrome or IGSF8-expressing cancers. In a further aspect, the present invention also relates to methods for detecting KIR3DL2.
Resumen de: WO2025042337A1
The present disclosure provides a method of treating acute myeloid leukemia in a 5 subject in need thereof, comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof to the subject. The present disclosure also provides a compound of Formula (II) or a salt, solvate or prodrug thereof. 10
Resumen de: WO2025039073A1
There is provided A compound of formula I, a salt or solvate thereof as described herein, for treating MYC positive cancers including lung cancer, leukemia, breast cancer, myeloproliferative disorders, colorectal cancer, medulloblastoma, renal, hepatocellular cancer, melanoma, ovarian cancer, prostate cancer, esophageal adenocarcinoma, liposarcoma, esophageal squamous cancer, gastrointestinal stromal tumor, glioma, myxofibrosarcoma, leiomyosarcoma, neuroblastoma, synovial sarcoma, mesothelioma, gastric cancer, thyroid cancer, lymphoma, osteosarcoma, rhabdomyosarcoma, fibrosarcoma, epithelial cancer, and neural cancer.
Resumen de: EP4512910A2
It aims to construct a technology in which the onset or progression of an aging state or a specific disease can be evaluated in an objective and highly reproducible manner, and in particular, to provide a method of detecting conjunctival diseases such as conjunctival MALT lymphoma, and to provide an aging biomarker that serves as an indicator of the aging state.A method of detecting a conjunctival disease using an ocular surface tissue, the method comprising a step of comparing a microbial community structure of a microbiota included in an ocular surface tissue specimen sampled from a healthy person, with a microbial community structure of a microbiota included in an ocular surface tissue specimen sampled from a subject to detect an ocular surface tissue specimen which is sampled from the subject evaluated as having the conjunctival disease based on a change in the microbial community structure between the healthy person and the subject, and an aging biomarker for detecting an aging state, the aging biomarker comprising a bacterial species which belongs to at least one family selected from Corynebacteriaceae family and Propionibacteriales family in an ocular surface tissue.
Resumen de: US2025034649A1
Provided are methods for prognosing a clinical outcome in a subject or diagnosing the subject with high-risk or stable smoldering multiple myeloma (SMM), comprising determining a 3D telomeres organization signature of a test sample from the subject, the test sample comprising plasma cells, applying a classification model to the 3D telomeres organization signature to obtain an output classification that is indicative of the clinical outcome or diagnosis of the subject. Also provided are methods for treating a subject with high-risk or stable SMM.
Resumen de: CN119072323A
The present invention provides a gene therapy, for example, using BAG3 (B cell lymphoma 2-associated immortalized gene 3) of an adeno-associated virus (AAV) vector. The promoter of the vector can be an MHCK7 promoter, a heart troponin T (hTNNT2) promoter, a heat shock protein 70 (HSP70) promoter or a ubiquitin C (UBC) promoter. The capsid may be an AAVrh.74 or AAV9 capsid or a functional variant thereof. In certain embodiments, the capsid is an AAVrh.74 capsid or a functional variant thereof. Other promoters or capsids may be used. The invention further provides methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the AAV vector, as well as other compositions and methods.
Resumen de: EP4513185A1
The present invention provides an in vitro method for predicting responsiveness to an allergen immunotherapy (AIT) in a subject having an allergy comprising measuring interleukin-6 (IL-6) and Suppressor Of Cytokine Signaling 3 (SOCS3), and optionally Sphingosine-1-phosphate receptor 1 (S1PR1) and/or B-cell lymphoma 3 (BCL3) in a biological sample from said subject at a time-point in the period spanning from 3 hours before to 24 hours after the timepoint when the maintenance dose of said immunotherapeutic is at least reached by the cumulative dose of said allergy immunotherapeutic. Also provided herein is a kit comprising means specifically adapted for measuring the quantity or expression levels of IL-6 and SOCS3, and optionally S1PR1 and/or BCL3 in a biological sample from a subject and the use thereof for predicting the response of a subject having an allergy to an AIT.
Resumen de: US2025057963A1
Provided herein are compounds (e.g., compounds of Formula (I)), their mechanism of action, and methods of treating diseases and disorders (e.g., cancer) using the compounds provided herein (e.g., compounds of Formula (I)). Also disclosed herein are N methods of inhibiting and degrading kinases (e.g., CDK9, CDK10, or anaplastic lymphoma kinase).
Resumen de: US2025057930A1
The invention features compositions and methods for treating anaplastic lymphoma kinase (ALK)-rearranged neoplasias including Non-Small Cell Lung Cancers (NSCLCs). The methods involve administering to a subject ALK peptides and/or polynucleotides encoding the ALK peptides, optionally in combination with an immune checkpoint inhibitor (ICI) and/or an ALK tyrosine kinase inhibitor (TKI).
Resumen de: WO2025038794A1
The present, disclosure relates to anti-SAA antibodies or fragments thereof, such as antibodies against human SAA1 or fragments thereof, that may be used in various therapeutic, prophylactic and diagnostic methods. The present antibodies or fragments thereof may be used to treat hematologic disorders such as acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome.
Resumen de: US2025057840A1
Compositions and methods for treatment of conditions associated with IDH1/2 mutation(s) are disclosed. The compositions and methods include administering an SRC inhibitor and a p70 S6 kinase/AKT (S6K/AKT) inhibitor. Examples of conditions associated with IDH1/2 mutation(s) include intrahepatic cholangiocarcinoma (ICC), oligodendrogliomas, astrocytomas, glioblastomas, leukemias, adenocarcinoma, gliomas, melanomas, oligoastrocytomas, invasive breast carcinoma, invasive ductal carcinoma, and myelodysplastic syndromes.
Resumen de: AU2025200680A1
Provided herein are small molecule inhibitors of NSD1, NSD2 and/or NSD3 activity, and methods of use thereof for the treatment of disease, including leukemia, breast cancer, osteosarcoma, lung and prostate cancers and other solid tumors as well as other diseases dependent on the activity of NSD1, NSD2 and/or NSD3.
Resumen de: US2025059283A1
The presently disclosed subject matter provides for methods and compositions for treating a neoplasia (e.g., multiple myeloma). It relates to chimeric antigen receptors (CARs) that specifically target Fc Receptor-like 5 (FcRL5), e.g., domain 9 of FcRL5, and immunoresponsive cells comprising such CARs. The presently disclosed FcRL5-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
Resumen de: US2025059209A1
Methods of treating cancer with human therapeutic compositions are provided, comprising compounds including a plurality of fused polycyclic moieties and a linker moiety. In certain embodiments, the compounds are the reaction products of aldehyde and harmaline components. The compositions exhibit anti-cancer properties, especially against lymphoma, leukemia, pancreatic, endometrial, ovarian, gastric, breast, renal, cervical, head and neck, and myeloma cell lines.
Resumen de: US2025059178A1
A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias. The inhibitors have the general structure 1:
Nº publicación: EP4508246A1 19/02/2025
Solicitante:
CELGENE CORP [US]
CELGENE CORPORATION
Resumen de: WO2023201348A1
Provided herein are methods of predicting the responsiveness of a lymphoma patient to a cancer treatment comprising clustering patients into subgroups of patients using gene expression levels. Also provided herein are methods of treating a lymphoma patient based on predicting the responsiveness of the lymphoma patient to a cancer treatment.
BOPI
Sede Electrónica
